H.C. Wainwright analyst Raghuram Selvaraju downgraded Entrada Therapeutics (TRDA) to Neutral from Buy without a price target saying the ELEVATE-44-201 initial cohort data “underwhelm.” The functional data appear more encouraging, but they are early, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
- Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
- Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
- Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
- Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer